mLV5FU2

mLV5FU2 is a chemotherapy regimen consisting of a modified version of the LV5FU2 protocol, which combines leucovorin (folinic acid) and 5-fluorouracil (5-FU). The "modified" aspect typically refers to adjustments in dosing or infusion duration to improve tolerability, especially in elderly or frail patients. In clinical trials such as those for metastatic colorectal cancer (mCRC), mLV5FU2 is often used as a backbone regimen and may be combined with other agents like aflibercept. The mechanism of action involves inhibition of thymidylate synthase by 5-FU, leading to impaired DNA synthesis and cell death in rapidly dividing tumor cells; leucovorin enhances the binding of 5-FU to its target enzyme. This regimen is primarily investigated for use in colorectal cancer[2][5].

Other names

modified LV5FU2modified leucovorin plus 5-fluorouracilmLV5-FU2mLV-5-FU2mLV 5-FU2